Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

PDE IV inhibitor selected for further study

June 14, 1996

Sankyo reveals PAF antagonists

June 14, 1996

LTB4 antagonists from Pfizer

June 14, 1996

Schering-Plough seeks Nasonex approval

June 14, 1996

Phase III trials on Kyowa Hakko's olopatidine HCl complete

June 7, 1996

SJC13: LPS-stimulated adhesion inhibitor

June 7, 1996

Searle discloses LTA4 hydrolase inhibitors

June 7, 1996

Sanofi Winthrop research reveals elastase inhibitors

May 31, 1996

Small-molecule alpha4 integrin antagonists generation disclosed by Biogen

May 31, 1996

Nikken Chemicals reports antiallergic/antiinflammatory N-hydroxyureas

May 31, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...